IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.50
−0.79%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-39.5%
Return on equity
-37.1%
Return on assets
-42.9%
Return on invested capital
0.00x
Asset turnover
-$42.6M
Cash from operations
$1.14
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026